近日，省药监局印发贯彻落实《安徽省全面深化药品医疗器械监管改革促进医药产业高质量发展若干措 施》（以下简称《若干措施》）清单，对涉及药品监管领域职能职责的措施进行细化分解，推动各项改 革任务落地见效。 对《若干措施》中涉及其他部门职责的改革措施，省药监局将推动纳入2026年全省药品安全工作要点进 行统筹部署与协同推进，确保我省各项改革举措全面落实、形成合力，推动我省医药产业高质量发展。 （来源：市场星报） 清单紧紧围绕《若干措施》部署的改革措施进行系统承接与细化，聚焦药品监管实际，针对强化药械研 发跟踪服务、支持服务中药新药上市、加强审评审批能力建设、提高药械监督检查效率、提升医药流通 新业态监管质效、大力提升智慧监管水平等18项具体改革举措，细化分解贯彻落实任务清单90项，并逐 项明确工作目标、责任处室单位和完成时限，实行清单化、闭环式管理。 ...

Core Viewpoint - The Shandong Provincial Government has issued an implementation opinion aimed at deepening the reform of drug and medical device regulation to promote high-quality development in the pharmaceutical industry, marking a significant step in enhancing drug safety and industry development [1][2]. Group 1: Key Measures - The implementation opinion outlines 29 measures across six areas to strengthen the cultivation of pharmaceutical innovation, support cutting-edge technology, enhance innovation platform construction, and promote the transformation of innovative drugs and devices [2]. - It aims to optimize the clinical trial ecosystem by encouraging medical institutions to undertake trials, improving the efficiency of ethical reviews, promoting the application of AI technology, and enhancing institutional management and services [2]. - The reform of review and approval processes is emphasized, including proactive alignment with the National Medical Products Administration, support for generic drug services, and the promotion of smart regulation for traditional Chinese medicine [2]. Group 2: Promotion and Internationalization - The opinion promotes the clinical use of innovative products by establishing a catalog of innovative products, accelerating the listing process, and improving the medical insurance payment mechanism [2]. - It encourages the international development of the industry through targeted investment attraction, supporting the export of raw materials and formulations, and enhancing international cooperation [2]. - There is a focus on strengthening quality supervision throughout the entire process, ensuring corporate responsibility, enhancing smart regulatory capabilities, and cracking down on illegal activities [2].

Core Viewpoint - The Shanghai government has introduced measures to enhance drug and medical device regulation, aiming to promote high-quality development in the pharmaceutical industry through reforms and improved services [1][2]. Group 1: Key Measures - The measures include 22 initiatives focusing on supporting research and development, enhancing review and approval efficiency, expanding high-level open cooperation, and strengthening regulatory capacity [1][2]. - Shanghai aims to accelerate the review and approval of overseas drug production applications and generic drug assessments, as well as promote pilot projects for biopharmaceuticals and cross-border production [2][3]. Group 2: Innovation and Technology - The integration of artificial intelligence with the pharmaceutical industry is emphasized, promoting AI applications in drug discovery, regulatory processes, and risk management [3]. - The establishment of a technology innovation base for pharmaceuticals and medical devices is planned, enhancing the use of AI in regulatory practices [3]. Group 3: Insurance and Accessibility - The Shanghai Medical Insurance Bureau will facilitate communication between insurance companies and innovative drug firms, exploring payment mechanisms based on treatment effectiveness to improve accessibility to innovative drugs and devices [3]. - The measures encourage the inclusion of new medical technologies and products in commercial health insurance coverage to meet diverse public needs [3]. Group 4: Intellectual Property Protection - Strengthening intellectual property protection is a key aspect of the measures, including expedited patent review services and enhanced administrative enforcement against patent infringement [3][4]. - The Shanghai Intellectual Property Bureau will focus on optimizing patent services, increasing administrative protection, and promoting patent commercialization to support industry development [4].

Core Viewpoint - Shanghai has issued measures to promote high-quality development in the pharmaceutical industry through regulatory reforms, innovation support, and enhanced approval processes [1] Group 1: Regulatory Reforms - The measures include 22 initiatives focusing on regulatory reforms to activate enterprise development and cultivate new production capabilities [1] - Optimization of the change process and guidelines for already listed drugs is proposed, along with pilot programs for segmented production of biological products [1] - The measures aim to deepen the pilot work for self-developed in vitro diagnostic reagents in medical institutions [1] Group 2: Industry Innovation - The initiatives emphasize enhancing service efficiency to promote industry innovation and accelerate regulatory support [1] Group 3: Approval Acceleration - The measures propose to improve the registration review efficiency for Class II medical devices, streamline consultation pathways, and enhance the quality of application materials [1] - The average registration cycle for first-time Class II medical devices is targeted to be compressed to within 6 months [1] Group 4: Integration and Standards - The focus is on strengthening the dual drive of standards and technology to seize new market opportunities [1]

Core Viewpoint - The Shanghai Municipal Government has issued measures to enhance drug and medical device regulation, aiming to promote high-quality development in the pharmaceutical industry through digital and intelligent regulatory practices [1] Group 1: Regulatory Enhancements - Strengthening full lifecycle digital and intelligent regulation by building a digital regulatory platform [1] - Improving variety and credit archives, and enhancing the application of innovative industry maps, AI-assisted review and approval, AI on-site supervision, and risk warning in regulation [1] Group 2: Medical Device and Traditional Chinese Medicine (TCM) Initiatives - Deepening the application of unique identification for medical devices and strengthening connections with healthcare and insurance systems, gradually expanding the range of varieties [1] - Continuously promoting full traceability of traditional Chinese medicine pieces and advancing the digital construction of TCM decoction delivery services [1]

Core Viewpoint - The Shanghai Municipal Government has issued measures to enhance the regulation of pharmaceuticals and medical devices, aiming to promote high-quality development in the pharmaceutical industry [1] Group 1: Regulatory Enhancements - Strengthening standard leadership by actively participating in the formulation and revision of national standards for pharmaceuticals and medical devices, as well as coordinating international standards [1] - Promoting the standardization research of cutting-edge technologies such as artificial intelligence medical devices, medical robots, brain-computer interfaces, particle therapy equipment, innovative traditional Chinese medicine diagnostic devices, and cell and gene therapy [1] Group 2: Traditional Chinese Medicine Standards - Continuing the research on standards for traditional Chinese medicine pieces, formula granules, and medical devices, relying on international standardization platforms like the International Organization for Standardization/Traditional Chinese Medicine Technical Committee (ISO/TC249) to establish international standards for traditional Chinese medicine [1] Group 3: Digitalization and Traceability - Supporting the formulation of group standards for the digital traceability of the production processes of pharmaceuticals and medical devices [1]

Core Viewpoint - Zhejiang Province has launched 20 specific reform measures to enhance the quality of the pharmaceutical and medical device industry, aiming for high-quality development through comprehensive regulatory reforms [1][5]. Group 1: Reform Measures - The implementation plan focuses on five key areas to enhance innovation capabilities, including strengthening the "three medical" collaborative mechanism and improving intellectual property protection [1]. - Zhejiang will optimize the review and approval process for drug changes and implement a "research-review linkage" for medical devices, reducing the review time for major changes to within 60 working days [2]. - A key product list will be compiled to provide comprehensive communication and guidance services for products in critical areas such as cancer and cardiovascular diseases, as well as for urgently needed and rare disease medications [3]. Group 2: Regulatory Capacity Building - The province will advance the research and application of new regulatory tools, standards, and methods, including evaluating the maturity of artificial intelligence medical device algorithms [3]. - The plan aims to enhance the overall safety level and innovation capabilities of drug regulation in Zhejiang, targeting international advanced standards by 2035 [1]. Group 3: Broader Implications - The reforms are expected to significantly promote the high-quality development of Zhejiang's pharmaceutical industry and provide a model for national regulatory reforms in the pharmaceutical and medical device sectors [5].

Core Viewpoint - The establishment of the Beijing-Tianjin-Hebei (Jing-Jin-Ji) Center for Drug and Medical Device Review and Inspection aims to enhance the quality and efficiency of drug and medical device regulation, promoting high-quality development in the pharmaceutical industry across the region [1][2]. Group 1: Overview of the Jing-Jin-Ji Center - The Jing-Jin-Ji Center was inaugurated on September 21 and will serve Beijing, Tianjin, Hebei, and Shandong, leveraging three major centers and four service stations to create a comprehensive service network for the biopharmaceutical industry [1][2]. - The center will provide technical services including research and development guidance, consultation, and review communication, focusing on accelerating the review and approval processes for urgently needed innovative drugs and medical devices [2][3]. Group 2: Services and Support for Enterprises - The Jing-Jin-Ji Center will establish flexible communication channels with enterprises to address uncertainties in drug development, offering in-depth discussions on key technical issues to streamline processes and enhance efficiency [3][4]. - The center will implement an annual training plan based on regional industry needs, providing targeted courses to meet diverse training demands [3][4]. Group 3: Integration and Standardization - The center's operations will be integrated into the unified work system of the National Medical Products Administration (NMPA), promoting standardized drug inspection and resource mutual recognition across the four regions [3][7]. - The establishment of the center is expected to enhance the quality of application materials and optimize the allocation of review resources, with over 1,200 enterprises served and more than 3,000 consultation issues resolved by 2025 [6][7]. Group 4: Strategic Collaboration and Future Goals - The Beijing government will strengthen strategic cooperation with the NMPA to create an efficient regional drug and medical device review system, positioning the Jing-Jin-Ji Center as a platform for high-quality integrated development and innovation in the pharmaceutical industry [7][8]. - The center aims to facilitate the integration of research, production, and clinical resources across the Jing-Jin-Ji and Shandong regions, aligning product development with clinical needs and regional health demands [7].

Core Points - The article discusses the implementation of the "Several Measures for Deepening Drug and Medical Device Regulation Reform in Shanxi Province" aimed at promoting high-quality development in the pharmaceutical industry [1][2] Group 1: Support for R&D Innovation - The measures include six specific actions to support drug and medical device R&D innovation, such as strengthening core technology research, accelerating drug development to preclinical research, and encouraging the innovation and industrialization of drugs and devices [1] Group 2: Improvement of Review and Approval Efficiency - Seven specific actions are proposed to enhance the quality and efficiency of drug and medical device review and approval processes, including optimizing review mechanisms and expediting the approval of urgently needed drugs and devices [1][2] Group 3: Promotion of Innovative Product Application - Four specific actions are outlined to accelerate the application and promotion of innovative products, such as encouraging enterprises to increase the application of innovative results and optimizing support for imports and exports [1] Group 4: Regulatory Compliance Enhancement - The measures emphasize strict regulatory responsibilities and propose seven specific actions to improve compliance levels in the pharmaceutical industry, including promoting the quality enhancement of generic drugs and increasing the efficiency of supervision and inspection [2] Group 5: Development of a Regulatory System - Four specific actions are suggested to build a regulatory system that aligns with industry development and safety needs, such as strengthening regulatory capacity building and advancing regulatory information technology [2]

Core Points - The provincial government is implementing reforms to accelerate the approval process for innovative medical devices and drugs, including establishing a green channel for priority reviews and compressing inspection timelines to enhance market access [1][2] Group 1: Approval Process Optimization - The provincial drug regulatory authority has introduced measures to optimize the review and approval mechanism, including a proactive approach with tailored strategies for each product and dedicated support teams [1] - The approval process for drug changes has been streamlined, reducing the minimum processing time for site changes from 195 days to 105 days, achieving an overall time reduction of over 40% [1] Group 2: Inspection and Registration Improvements - The registration inspection for low-risk drug varieties has been optimized, with the required batch quantity for inspection reduced from three times to two times the full inspection quantity [2] - The inspection timeline for registered medical devices has been compressed to 20 working days, and emergency approvals are being implemented to expedite the process for urgently needed medical devices and drugs [2] Group 3: Focus on Rare Diseases and Urgent Needs - The approval process for drugs and medical devices related to rare diseases has been expedited, with the number of required inspection batches reduced from three to one, and the batch quantity requirement also decreased [2] - Clinical urgent medical devices are prioritized in the approval process, with the approval timeline reduced from 58 working days to 30 working days [2]